Lymphoma, Follicular persistent Evidence | Lymphoma, Follicular Progressive Evidence | Ann Arbor lymphoma staging system | Marginal Zone B-Cell Lymphoma Evidence
Item
patients must have evidence of persistent or progressive follicular grade, 1, 2 or 3 or marginal zone b-cell non-hodgkin's lymphoma.
boolean
C0024301 (UMLS CUI [1,1])
C0205322 (UMLS CUI [1,2])
C3887511 (UMLS CUI [1,3])
C0024301 (UMLS CUI [2,1])
C0205329 (UMLS CUI [2,2])
C3887511 (UMLS CUI [2,3])
C0432516 (UMLS CUI [3])
C1367654 (UMLS CUI [4,1])
C3887511 (UMLS CUI [4,2])
systemic therapy Course Quantity Lymphoma | rituximab | Disease Progression | Systemic Chemotherapy
Item
must have received at least two prior courses of systemic treatment including at least one treatment of rituximab (lymphoma must not have progressed during their most recent systemic chemotherapy treatment).
boolean
C1515119 (UMLS CUI [1,1])
C0750729 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0024299 (UMLS CUI [1,4])
C0393022 (UMLS CUI [2])
C0242656 (UMLS CUI [3])
C1883256 (UMLS CUI [4])
Lymphoma CD20 Antigen Expression Evidence | Renal function | Liver function
Item
must have evidence that their lymphoma expresses cd20 antigen and have adequate renal and hepatic function.
boolean
C0024299 (UMLS CUI [1,1])
C0054946 (UMLS CUI [1,2])
C0017262 (UMLS CUI [1,3])
C3887511 (UMLS CUI [1,4])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Chemotherapy | Therapeutic radiology procedure | Immunosuppressive Agents | Cytokine therapy
Item
received chemotherapy, radiation therapy, immunosuppressants or cytokine treatment within 4 weeks prior to study entry.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
C0199974 (UMLS CUI [4])
Hydronephrosis Obstructive
Item
have active obstructive hydronephrosis.
boolean
C0020295 (UMLS CUI [1,1])
C0549186 (UMLS CUI [1,2])
Transplantation of autologous hematopoietic stem cell | Allogeneic Stem Cell Transplantation
Item
had prior autologous hematopoietic stem cell transplant or any allogenic stem cell transplant.
boolean
C1831743 (UMLS CUI [1])
C2242529 (UMLS CUI [2])
Communicable Disease Requirement Intravenous antibiotic therapy
Item
have active infection requiring iv antibiotics.
boolean
C0009450 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0559680 (UMLS CUI [1,3])
Metastatic malignant neoplasm to brain | Metastatic Malignant Neoplasm to the Leptomeninges
Item
have brain or leptomeningeal metastasis.
boolean
C0220650 (UMLS CUI [1])
C1704231 (UMLS CUI [2])
Allergic Reaction Iodine | Radioimmunotherapy | Antineoplastic Agents Approved | Antineoplastic Agents Investigational
Item
had previous allergic reaction to iodine, previously received radioimmunotherapy or are currently receiving approved or experimental anti-cancer drugs.
boolean
C1527304 (UMLS CUI [1,1])
C0021968 (UMLS CUI [1,2])
C0085101 (UMLS CUI [2])
C0003392 (UMLS CUI [3,1])
C0205540 (UMLS CUI [3,2])
C0003392 (UMLS CUI [4,1])
C1517586 (UMLS CUI [4,2])
Pregnancy | Breast Feeding | HIV Infections | Human anti-mouse antibody Positive
Item
patients who are pregnant or breast feeding, have known hiv infection, or are human anti-murine antibody (hama) positive.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0019693 (UMLS CUI [3])
C1291910 (UMLS CUI [4,1])
C1514241 (UMLS CUI [4,2])
criteria Other
Item
other criteria will be evaluated at the screening visit.
boolean
C0243161 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])